PeptideStack
5.2kquestions
20kanswers
220users

How many vials from a QST lot should I send for an HPLC purity test?

Asked 1 Feb 2025Modified 15 months agoViewed 15k times
22

Conditions: QST · an HPLC purity test.

I want the working, not the result — I need to be able to redo it with different numbers.

I care about the precision as well as the value — I want to know how many figures are real.

How many significant figures are actually justified here?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

261 questions
shareeditfollowflag
SK
askeds_kalniete47k381 Feb 2025

5 Answers

Accepted answer first, then by votes
119

Accepted answer

The part that matters: sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

The underlying point is that if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 8 May 2025 by tobias_maartens — added the method parameters

shareimprove this answerflag
TM
answered · acceptedtobias_maartens94k25821 Apr 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
46

Worth being precise here: the honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
RO
answeredrae_oyelowo21k382 May 2025
34

Stated carefully, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
DV
answereddead_volume49k3830 Mar 2025
2Small correction: the units in the third paragraph should be micrograms, not milligrams. – lane_transit 7 months ago
Do you have a reference for the last claim? Not disputing it, just want to read it. – h_villanueva 5 months ago
add a comment
27

Two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
M4
answeredmz_411399k25810 Apr 2025
26

If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
HV
answeredh_villanueva50k388 Mar 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.